Health Catalyst stock (US42226A1079): Shares jump after recent trading update

Health Catalyst shares moved sharply in recent trading, while the company’s latest reported results showed higher revenue but a wider loss in the first half of 2025.

Health Catalyst shares have been volatile in recent sessions, with market data showing a jump of about 7.98% to $1.28 on May 18, 2026, according to Invezz as of 05/18/2026. For US investors, the stock sits in the healthcare data and analytics niche, a segment tied to hospital spending, software adoption, and healthcare IT budgets.

Health Catalyst’s most recent financial disclosure cited in the search results showed six-month revenue of $160.1 million for the period ended June 30, 2025, up from $150.6 million a year earlier, driven by recurring technology revenue of $104.4 million versus $94.6 million. The same report also showed a net loss of $64.7 million, wider than the $34.1 million loss in the comparable period, reflecting operating costs and a $28.8 million goodwill impairment, according to Stock Titan SEC filings page as of 2025.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Health Catalyst, Inc.
• Sector/industry: Healthcare data and analytics software
• Headquarters/country: United States
• Core markets: Hospitals, health systems, and healthcare providers
• Key revenue drivers: Technology revenue and recurring software services
• Home exchange/listing venue: Nasdaq: HCAT
• Trading currency: U.S. dollars

Health Catalyst: core business model

Health Catalyst sells software and analytics tools designed to help healthcare organizations manage performance, data integration, and operational workflows. That model matters because hospital systems often buy technology in multi-year cycles, so recurring revenue can be more stable than one-time implementation work.

The company’s reported first-half 2025 figures underline that mix. Technology revenue made up the larger share of sales in the period cited above, while management also had to absorb a goodwill impairment charge. For investors, that combination points to a business that can still grow top-line revenue even when profitability remains under pressure.

Main revenue and product drivers for Health Catalyst

The most important driver in the company’s reported figures was recurring technology revenue, which increased year over year in the six-month period ended June 30, 2025. That category is especially relevant for US investors because it gives a window into how much of the business is tied to repeat software usage rather than one-off services.

Market watchers often focus on whether software vendors in healthcare can convert revenue growth into smaller losses over time. In Health Catalyst’s case, the company posted higher sales but a wider net loss in the same period, suggesting that execution on cost control remains a central issue. The stock’s recent jump also shows how quickly sentiment can move in a thinly valued small-cap name.

Health Catalyst operates in a sector that has direct exposure to US healthcare spending, value-based care initiatives, and provider technology budgets. That makes the company relevant not only as a standalone software name, but also as part of broader demand trends in US health systems and digital transformation.

Why Health Catalyst matters for US investors

Health Catalyst is listed on Nasdaq and trades in U.S. dollars, so it is directly accessible to domestic retail investors. The stock’s low share price and market-cap profile can make it sensitive to earnings releases, contract updates, and trading momentum. That combination often attracts short-term attention even when the underlying fundamental picture is still mixed.

The company also sits in a market where spending decisions can be influenced by reimbursement pressure, regulatory changes, and IT budget discipline. For that reason, any improvement in recurring revenue or narrowing losses can matter disproportionately to valuation expectations.

Conclusion

Health Catalyst remains a name that blends growth potential with continued earnings pressure. The latest reported figures showed revenue improvement, but they also showed that profitability is not yet on a steady path. Recent trading action suggests that investors are still reacting quickly to any sign of momentum in the stock.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.